These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36802946)

  • 21. Concomitant Versus Individual Administration of Antithrombin and Thrombomodulin for Sepsis-Induced Disseminated Intravascular Coagulation: A Nationwide Japanese Registry Study.
    Umemura Y; Yamakawa K; Hayakawa M; Kudo D; Fujimi S
    Clin Appl Thromb Hemost; 2018 Jul; 24(5):734-740. PubMed ID: 29471674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
    Yamakawa K; Ogura H; Fujimi S; Morikawa M; Ogawa Y; Mohri T; Nakamori Y; Inoue Y; Kuwagata Y; Tanaka H; Hamasaki T; Shimazu T
    Intensive Care Med; 2013 Apr; 39(4):644-52. PubMed ID: 23361628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antithrombin supplementation and risk of bleeding in patients with sepsis-associated disseminated intravascular coagulation.
    Iba T; Gando S; Saitoh D; Wada H; Di Nisio M; Thachil J
    Thromb Res; 2016 Sep; 145():46-50. PubMed ID: 27479532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk stratification utilizing sequential organ failure assessment (SOFA) score, antithrombin activity, and demographic data in sepsis-associated disseminated intravascular coagulation (DIC).
    Iba T; Maier CL; Tanigawa T; Levy JH
    Sci Rep; 2023 Dec; 13(1):22502. PubMed ID: 38110515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal patient selection for anticoagulant therapy in sepsis: an evidence-based proposal from Japan.
    Umemura Y; Yamakawa K
    J Thromb Haemost; 2018 Mar; 16(3):462-464. PubMed ID: 29316171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis.
    Wiedermann CJ; Kaneider NC
    Blood Coagul Fibrinolysis; 2006 Oct; 17(7):521-6. PubMed ID: 16988545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey.
    Iba T; Saitoh D; Wada H; Asakura H
    Crit Care; 2014 Sep; 18(5):497. PubMed ID: 25220851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation.
    Levi M; de Jonge E; van der Poll T
    Crit Care Med; 2001 Jul; 29(7 Suppl):S90-4. PubMed ID: 11445740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study.
    Yamakawa K; Fujimi S; Mohri T; Matsuda H; Nakamori Y; Hirose T; Tasaki O; Ogura H; Kuwagata Y; Hamasaki T; Shimazu T
    Crit Care; 2011; 15(3):R123. PubMed ID: 21569368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation.
    Vincent JL; Ramesh MK; Ernest D; LaRosa SP; Pachl J; Aikawa N; Hoste E; Levy H; Hirman J; Levi M; Daga M; Kutsogiannis DJ; Crowther M; Bernard GR; Devriendt J; Puigserver JV; Blanzaco DU; Esmon CT; Parrillo JE; Guzzi L; Henderson SJ; Pothirat C; Mehta P; Fareed J; Talwar D; Tsuruta K; Gorelick KJ; Osawa Y; Kaul I
    Crit Care Med; 2013 Sep; 41(9):2069-79. PubMed ID: 23979365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in plasma levels of natural anticoagulants in disseminated intravascular coagulation: high prognostic value of antithrombin and protein C in patients with underlying sepsis or severe infection.
    Choi Q; Hong KH; Kim JE; Kim HK
    Ann Lab Med; 2014 Mar; 34(2):85-91. PubMed ID: 24624342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sepsis-related coagulopathy treatment based on the disseminated intravascular coagulation diagnostic criteria: a post-hoc analysis of a prospective multicenter observational study.
    Wada T; Yamakawa K; Kabata D; Abe T; Fujishima S; Kushimoto S; Mayumi T; Ogura H; Saitoh D; Shiraishi A; Otomo Y; Gando S;
    J Intensive Care; 2023 Mar; 11(1):8. PubMed ID: 36872342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study.
    Hayakawa M; Yamakawa K; Saito S; Uchino S; Kudo D; Iizuka Y; Sanui M; Takimoto K; Mayumi T; Ono K;
    Thromb Haemost; 2016 Jun; 115(6):1157-66. PubMed ID: 26939575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis.
    Zarychanski R; Abou-Setta AM; Kanji S; Turgeon AF; Kumar A; Houston DS; Rimmer E; Houston BL; McIntyre L; Fox-Robichaud AE; Hébert P; Cook DJ; Fergusson DA;
    Crit Care Med; 2015 Mar; 43(3):511-8. PubMed ID: 25493972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients.
    Takazono T; Nakamura S; Imamura Y; Yoshioka S; Miyazaki T; Izumikawa K; Sawai T; Matsuo N; Yanagihara K; Suyama N; Kohno S
    J Infect Chemother; 2014 Aug; 20(8):484-8. PubMed ID: 24855912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Recombinant Human Soluble Thrombomodulin on Coagulation-Related Variables in Patients With Sepsis-Induced Disseminated Intravascular Coagulation: A Retrospective Observational Study.
    Mitaka C; Kawagoe I; Satoh D; Hayashida M
    Clin Appl Thromb Hemost; 2021; 27():10760296211050356. PubMed ID: 34859680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistent and Late-Onset Disseminated Intravascular Coagulation Are Closely Related to Poor Prognosis in Patients with Sepsis.
    Matsuoka T; Yamakawa K; Iba T; Homma K; Sasaki J
    Thromb Haemost; 2024 May; 124(5):399-407. PubMed ID: 37871648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Age Is Associated With the Efficacy of Anticoagulant Therapies Against Sepsis-Induced Disseminated Intravascular Coagulation.
    Takahashi K; Umemura Y; Yamakawa K; Ogura H; Shimazu T
    Clin Appl Thromb Hemost; 2021; 27():10760296211033030. PubMed ID: 34278836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of Measuring Changes in SOFA Score for the Prediction of 28-Day Mortality in Patients With Sepsis-Associated Disseminated Intravascular Coagulation.
    Iba T; Arakawa M; Mochizuki K; Nishida O; Wada H; Levy JH
    Clin Appl Thromb Hemost; 2019; 25():1076029618824044. PubMed ID: 30808223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Combined Thrombomodulin and Antithrombin in Anticoagulant Therapy for Acute Cholangitis-induced Disseminated Intravascular Coagulation.
    Morita N; Nakahara K; Morita R; Suetani K; Michikawa Y; Sato J; Tsuji K; Ikeda H; Matsunaga K; Watanabe T; Matsumoto N; Okuse C; Suzuki M; Itoh F
    Intern Med; 2019 Apr; 58(7):907-914. PubMed ID: 30449812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.